About Us
A Company that Pursues the Principles of Health and Life
History
Present 2011
2020
  • 05
    Signed a technology transfer contract for commercialization of PDRN with BNF Solution Co., Ltd.
  • 04
    Secured new candidates for COVID-19 treatment
  • 03
    Signed a business agreement with Interbiome in the United States to establish and operate cGMP manufacturing facilities for virus-based gene therapy products
2019
  • Acquired ISO 37001 (corruption prevention management system) certification
    10
    Acquired ISO 37001 (corruption prevention management system) certification
  • Selected as the best job provider in Korea (Ministry of Employment and Labor)
    07
    Selected as the best job provider in Korea (Ministry of Employment and Labor)
  • 03
    Signed a memorandum of understanding for the establishment of a joint venture for commercial production of next-generation CAR-T treatments with CUROCELL.
  • Awarded an exemplary taxpayer citation (Director of National Tax Service)
    03
    Awarded an exemplary taxpayer citation (Director of National Tax Service)
  • 02
    Decision made to build chemical pharmaceuticals cGMP plant in Chungju
  • Declared vision 'BEST till 2023'
    01
    Declared vision 'BEST till 2023'
2018
  • 10
    Signed investment contract with Neuracle Genetics Co., Ltd.
  • 09
    Signed business agreement with GNP Bioscience for the development of natural medicines and health functional foods
  • 08
    Signed antibody treatment joint development contract with Neuracle Science Co., Ltd.
  • 05
    Signed joint development contract for gene therapy products with GNP Bioscience Co., Ltd.
2017
  • 10
    Signed business agreement for natural drug development with FINZELBERG, Germany
  • Commenced construction of cGMP plant for gene therapy products in Chungju
    08
    Commenced construction of cGMP plant for gene therapy products in Chungju
  • 07
    Vascular and neurological disease gene therapy drug approved in US for phase 3 (2nd) clinical trial for treatment of diabetic neuropathy
2016
  • 12
    Head office relocated (Yongsan-gu, Seoul → Gangnam-gu, Seoul)
  • 09
    Vascular and neurological disease gene therapy drug approved in Korea for phase 2 clinical trial for treatment of amyotrophic lateral sclerosis (ALS)
  • 07
    Vascular and neurological disease gene therapy drug approved for phase 2 clinical trial for treatment of coronary artery disease (CAD) in Korea
  • 05
    Vascular and neurological disease gene therapy designated for fast track development for treatment of amyotrophic lateral sclerosis (ALS) by the US Food and Drug Administration
2015
  • 09
    Vascular and neurological disease gene therapy drug approved for phase 3 clinical trial for treatment of chronic non-healing diabetic/ischemic ulcers (NHU)
  • 04
    Vascular and neurological disease gene therapy drug approved for phase 3 (1st) of clinical trial for treatment of diabetic neuropathy in US
2014
  • 11
    Vascular and neurological disease gene therapy drug phase 2 clinical trial for treatment of diabetic neuropathy in completed US/Korea
  • 05
    Acquired site for Chungju Bio/Chemical cGMP plant
  • 04
    Vascular and neurological disease gene therapy drug phase 2 clinical trial for treatment of critical limb ischemia (CLI) approved in US/Korea
  • 02
    Vascular and neurological disease gene therapy approved as orphan drug for treatment of amyotrophic lateral sclerosis (ALS) the US Food and Drug Administration
2013
  • 12
    Completed phase 1 clinical trial (breast cancer) in Korea for anticancer gene therapy
  • 12
    Signed global commercialization joint development contract with ViroMed Co., Ltd. for vascular and neurological disease gene therapy drug for treating amyotrophic lateral sclerosis (ALS)
2012
  • 07
    Concluded contract for exporting antibiotic arbekacin sulfate to Russia
  • 07
    Concluded technology and worldwide sales rights transfer contract with ViroMed for chronic hepatitis B DNA vaccine
2011
  • 10
    Concluded contract to export antibiotic arbekacin sulfate product/raw materials to China
  • 07
    Presented KRW 100 Billion Venture Business Award (Small and Medium Business Administration, Korea Venture Business Association)
  • 01
    Concluded contract for exporting antibiotic arbekacin sulfate to India
2010 2001
2010
  • Listed on Korea Stock Exchange
    06
    Listed on Korea Stock Exchange
  • Central Research Center relocated (Dongbinggo-dong, Yongsan-gu, Seoul → Pyeongchon-dong, Dongan-gu, Anyang-si)
    02
    Central Research Center relocated (Dongbinggo-dong, Yongsan-gu, Seoul → Pyeongchon-dong, Dongan-gu, Anyang-si)
2009
  • Awarded model taxpayer citation (Minister of Strategy and Finance)
    03
    Awarded model taxpayer citation (Minister of Strategy and Finance)
2008
  • 01
    Signed anticancer gene therapy joint development contract with ViroMed Co., Ltd.
2004
  • 01
    Signed joint development contract with ViroMed Co., Ltd. for vascular and neurological disease gene therapy drug
2003
  • 12
    Selected as an INNOBIZ company (Small and Medium Business Administration)
  • 04
    Selected as an excellent technology company (Korea Technology Finance Corporation)
2000 1950
2000
  • 11
    Developed Teicoplanin as a first generic API
  • 03
    Became the first company in Korea to release Arbekacin sulfate, which is specially effective against MRSA
  • 01
    Introduced original contrast agent (Optiray) product
1999
  • 03
    Synthesized antibiotic Arbekacin sulfate as a first generic manufacturer, and commenced export to Japan
1994
  • Completion of fermentation plant (located in Deoksan-myeon, Jincheon-gun, Chungcheongbuk-do, Korea)
    10
    Completion of fermentation plant (located in Deoksan-eup, Jincheon-gun, Chungcheongbuk-do, Korea)
1991
  • Changed the company name from REYON Synthetics Co., Ltd. to REYON Pharmaceutical Co., Ltd.
    03
    Changed the company name from REYON Synthetics Co., Ltd. to REYON Pharmaceutical Co., Ltd.
1989
  • Completed construction of Jincheon Factory (located in Deoksan-eup, Jincheon-gun, Chungcheongbuk-do, Korea)
    08
    Completed construction of Jincheon Factory (located in Deoksan-eup, Jincheon-gun, Chungcheongbuk-do, Korea)
1988
  • Established affiliated REYON Central Research Center
    01
    Established affiliated REYON Central Research Center
1986
  • 09
    Joint development of Streptokinase,streptodornase (SKD) manufacturing technology (KIST)
1964
  • Incorporated as REYON Synthetics Co., Ltd.
    11
    Incorporated as REYON Synthetics Co., Ltd.
1955
  • Established REYON Research Center
    02
    Established REYON Research Center
  • Present ~ 2011
  • 2010 ~ 2001
  • 2000 ~ 1950